Posted by Michael Wonder on 05 Jun 2023
Amarin Partner EddingPharm receives regulatory approval for Vascepa (icosapent ethyl) in Mainland China
1 June 2023 - Vascepa approved by the NMPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridaemia (≥ 500 mg/dL).
Amarin Corporation today announced that its commercial partner in China EddingPharm, has received regulatory approval for Vascepa (icosapent ethyl) from China’s NMPA.
